Posted: May 11, 2025 at 2:46 am
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7-10, in Amsterdam, the Netherlands.
Posted: May 11, 2025 at 2:46 am
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
Read more from the original source:
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
Posted: May 11, 2025 at 2:46 am
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to provide a corporate and financial update.
See the original post here:
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
Posted: May 11, 2025 at 2:46 am
New corporate identity reflects the continued evolution toward developing the Stratus Prime™ platform to deliver on-demand, Prime HSCs™ and Prime HPCs™ for curative blood and immune system restoration New corporate identity reflects the continued evolution toward developing the Stratus Prime™ platform to deliver on-demand, Prime HSCs™ and Prime HPCs™ for curative blood and immune system restoration
Read more here:
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
Posted: May 11, 2025 at 2:46 am
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am -12:10 pm EDT (15:40-16:10 GMT / 17:40-18:10 CET).
Go here to read the rest:
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
Posted: May 11, 2025 at 2:46 am
Conference Call and Webcast Today at 8:30 a.m. ET
View post:
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Posted: May 11, 2025 at 2:46 am
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit's global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit’s reach across a highly valuable Asia-Pacific pharmaceutical region.
Posted: May 11, 2025 at 2:46 am
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.
Follow this link:
Celularity Announces Full Year 2024 Operating and Financial Results
Posted: May 11, 2025 at 2:46 am
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
Read more:
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
